Skip to main content

Cancer Epigenetics - Solid Tumors

Section information

Section Editors : Maria Berdasco and Carmen Jeronimo 

Associate Editors : Nita Ahuja, Tiziana Bonaldi (histones), Rene Cortese, James Flanagan (cervical/ovarian), Thomas Fleischer, Mario Fraga, Michéle Hoffmann (prostate), Bozena Kaminska (gliomas), Gwen Lomberk, Arpad Patai (colorectal/GI cancers), Qian Tao, Raul Urrutia, Stefan Wiemann (breast), Keishi Yamashita

The development of genome-wide techniques has rapidly improved the comprehensive knowledge of epigenetic alterations in cancer. Currently, a vast number of genes and their associated molecular pathways that show epigenetic differences between normal and tumoral cells have been identified, emphasizing the crucial role of epigenetic factors in cancer etiology and progression.  This section publishes original epigenetic research focused on the identification of epigenetic biomarkers associated with cancer diagnosis or tumor progression. Manuscripts on epigenetic biomarkers leading to a better definition of therapy response are also accepted (pharmacoepigenetics). Submissions on reports from human clinical trials providing insights on the clinical application of epigenetic biomarkers are welcomed.

Page 6 of 8

  1. The idea that changes to the host immune system are critical for cancer progression was proposed a century ago and recently regained experimental support.

    Authors: Yonghong Zhang, Sophie Petropoulos, Jinhua Liu, David Cheishvili, Rudy Zhou, Sergiy Dymov, Kang Li, Ning Li and Moshe Szyf
    Citation: Clinical Epigenetics 2018 10:8
  2. Chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and epigenetic events underlie lung cancer (LC) development. The study objective was that lung tumor expression levels of specific mic...

    Authors: Mercè Mateu-Jimenez, Víctor Curull, Alberto Rodríguez-Fuster, Rafael Aguiló, Albert Sánchez-Font, Lara Pijuan, Joaquim Gea and Esther Barreiro
    Citation: Clinical Epigenetics 2018 10:7
  3. This study was aimed at understanding whether bronchial biopsy specimen can be used as a surrogate for DNA methylation analysis in surgically resected lung cancer.

    Authors: Sang-Won Um, Hong Kwan Kim, Yujin Kim, Bo Bin Lee, Dongho Kim, Joungho Han, Hojoong Kim, Young Mog Shim and Duk-Hwan Kim
    Citation: Clinical Epigenetics 2017 9:131
  4. Esophageal squamous cell carcinoma (ESCC) is one of the 10 most incident cancer types in the world, and it is mainly associated with tobacco and alcohol consumption. ESCC mortality rates stand very close to it...

    Authors: Isabela Martins Gonzaga, Sheila Coelho Soares Lima, Marina Chianello Nicolau, Pedro Nicolau-Neto, Nathalia Meireles da Costa, Tatiana de Almeida Simão, Hector Hernandez-Vargas, Zdenko Herceg and Luis Felipe Ribeiro Pinto
    Citation: Clinical Epigenetics 2017 9:130
  5. DNA methylation has been implicated as a promising biomarker for precise cancer diagnosis. However, limited DNA methylation-based biomarkers have been described in esophageal squamous cell carcinoma (ESCC).

    Authors: Weilin Pu, Chenji Wang, Sidi Chen, Dunmei Zhao, Yinghui Zhou, Yanyun Ma, Ying Wang, Caihua Li, Zebin Huang, Li Jin, Shicheng Guo, Jiucun Wang and Minghua Wang
    Citation: Clinical Epigenetics 2017 9:129
  6. Wilms tumor (WT) is a curable pediatric renal malignancy, but there is a need for new molecular biomarkers to improve relapse risk-directed therapy. Somatic alterations occur at relatively low frequencies wher...

    Authors: Bruna M. de Sá Pereira, Rafaela Montalvão-de-Azevedo, Paulo Antônio Faria, Neimar de Paula Silva, Pedro Nicolau-Neto, Mariana Maschietto, Beatriz de Camargo and Sheila Coelho Soares Lima
    Citation: Clinical Epigenetics 2017 9:128
  7. Colorectal cancer (CRC) screening is the most efficient strategy to reduce disease-related mortality. Frequent aberrant DNA methylation is known to occur in selected genes and early during CRC development, whi...

    Authors: Tae Jeong Oh, Hyun Il Oh, Yang Yei Seo, Dongjun Jeong, Changjin Kim, Hyoun Woo Kang, Yoon Dae Han, Hyun Cheol Chung, Nam Kyu Kim and Sungwhan An
    Citation: Clinical Epigenetics 2017 9:126
  8. SHOX2 and SEPT9 methylation in circulating cell-free DNA (ccfDNA) in blood are established powerful and clinically valuable biomarkers for diagnosis, staging, prognosis, and monitoring...

    Authors: Luka de Vos, Heidrun Gevensleben, Andreas Schröck, Alina Franzen, Glen Kristiansen, Friedrich Bootz and Dimo Dietrich
    Citation: Clinical Epigenetics 2017 9:125
  9. In the last years, the explosion of high throughput sequencing technologies has enabled epigenome-wide analyses, allowing a more comprehensive overview of the oropharyngeal squamous cell carcinoma (OPSCC) epig...

    Authors: Paolo Boscolo-Rizzo, Carlo Furlan, Valentina Lupato, Jerry Polesel and Elisabetta Fratta
    Citation: Clinical Epigenetics 2017 9:124
  10. Hwang et al. recently showed that VGF substantially contributes to the resistance of human lung cancer cells towards epidermal growth factor receptor kinase inhibitors. This was further linked to enhanced epit...

    Authors: Sebastian Marwitz, Lena Heinbockel, Swetlana Scheufele, Dörte Nitschkowski, Christian Kugler, Sven Perner, Martin Reck, Ole Ammerpohl and Torsten Goldmann
    Citation: Clinical Epigenetics 2017 9:123
  11. Both defective DNA methylation and active DNA demethylation processes are emerging as important risk factors in chronic lymphocytic leukemia (CLL). However, associations between 5-cytosine epigenetic markers a...

    Authors: Cristina Bagacean, Christelle Le Dantec, Christian Berthou, Adrian Tempescul, Hussam Saad, Anne Bordron, Mihnea Zdrenghea, Victor Cristea, Nathalie Douet-Guilbert and Yves Renaudineau
    Citation: Clinical Epigenetics 2017 9:122
  12. HPV DNA testing as a primary screening marker is being implemented in several countries. Due to the high HPV prevalence in the screening population, effective triage strategies for HPV-positive cases are requi...

    Authors: Martina Schmitz, Kristina Wunsch, Heike Hoyer, Cornelia Scheungraber, Ingo B. Runnebaum, Alfred Hansel and Matthias Dürst
    Citation: Clinical Epigenetics 2017 9:118
  13. Hepatocellular carcinoma is the fifth most common malignancy and the third leading cause of cancer-related death worldwide. Dysregulation of HomeoboxD10 (HOXD10) was found to suppress or promote cancer progres...

    Authors: Yulin Guo, Yaojun Peng, Dan Gao, Meiying Zhang, Weili Yang, Enqiang Linghu, James G. Herman, François Fuks, Guanglong Dong and Mingzhou Guo
    Citation: Clinical Epigenetics 2017 9:116
  14. ZNF331 was reported to be a transcriptional repressor. Methylation of the promoter region of ZNF331 has been found frequently in human esophageal and gastric cancers. The function and methylation status of ZNF...

    Authors: Yuzhu Wang, Tao He, James G. Herman, Enqiang Linghu, Yunsheng Yang, François Fuks, Fuyou Zhou, Linjie Song and Mingzhou Guo
    Citation: Clinical Epigenetics 2017 9:115

    The Correction to this article has been published in Clinical Epigenetics 2018 10:36

  15. Multiple aberrant microRNA expression has been reported in gastric cancer. Among them, microRNA-335-5p (miR-335), a microRNA regulated by DNA methylation, has been reported to possess both tumor suppressor and...

    Authors: Alejandra Sandoval-Bórquez, Iva Polakovicova, Nicolás Carrasco-Véliz, Lorena Lobos-González, Ismael Riquelme, Gonzalo Carrasco-Avino, Carolina Bizama, Enrique Norero, Gareth I. Owen, Juan C. Roa and Alejandro H. Corvalán
    Citation: Clinical Epigenetics 2017 9:114

    The Correction to this article has been published in Clinical Epigenetics 2021 13:50

  16. Recent studies have identified age-related changes in DNA methylation patterns in normal and cancer tissues in a process that is called epigenetic drift. However, the evolving patterns, functional consequences...

    Authors: E. Georg Luebeck, Kit Curtius, William D. Hazelton, Sean Maden, Ming Yu, Prashanthi N. Thota, Deepa T. Patil, Amitabh Chak, Joseph E. Willis and William M. Grady
    Citation: Clinical Epigenetics 2017 9:113
  17. KIBRA has been suggested as a key regulator of the Hippo signaling pathway, regulating organ size, cell contact inhibition, tissue regeneration as well as tumorigenesis and cystogenesis. We recently reported t...

    Authors: Katrin Schelleckes, Boris Schmitz, Giuliano Ciarimboli, Malte Lenders, Hermann J. Pavenstädt, Edwin Herrmann, Stefan-Martin Brand and Eva Brand
    Citation: Clinical Epigenetics 2017 9:109
  18. Respiratory diseases hold several genome, epigenome, and transcriptional aberrations as a cause of the accumulated damage promoted by, among others, environmental risk factors. Such aberrations can also come a...

    Authors: Abril Marcela Herrera-Solorio, Leonel Armas-López, Oscar Arrieta, Joaquín Zúñiga, Patricia Piña-Sánchez and Federico Ávila-Moreno
    Citation: Clinical Epigenetics 2017 9:98
  19. Patients with early colorectal cancer (stages I–II) generally have a good prognosis, but a subgroup of 15–20% experiences relapse and eventually die of disease. Occult metastases have been suggested as a marke...

    Authors: Guro E. Lind, Marianne Guriby, Terje Ahlquist, Israr Hussain, Marine Jeanmougin, Kjetil Søreide, Hartwig Kørner, Ragnhild A. Lothe and Oddmund Nordgård
    Citation: Clinical Epigenetics 2017 9:97
  20. Aberrant CpG island methylation has been increasingly recognized as a common event in myelodysplastic syndrome (MDS). To date, most of the previous studies of miR-124 in MDS have focused on epigenetic changes ...

    Authors: Hong Wang, Tong-Tong Zhang, Song Jin, Hong Liu, Xiang Zhang, Chang-Geng Ruan, De-Pei Wu, Yue Han and Xiao-Qin Wang
    Citation: Clinical Epigenetics 2017 9:91
  21. Imprinted domains have been identified as targets for aberrant DNA methylation during carcinogenesis, but it remains unclear when these epigenetic alterations occur and how they contribute to tumor progression...

    Authors: Corey L. Bretz, Ingeborg M. Langohr and Joomyeong Kim
    Citation: Clinical Epigenetics 2017 9:90
  22. DNA methylation has started a recent revolution in genomics biology by identifying key biomarkers for multiple cancers, including oral squamous cell carcinoma (OSCC), the most common head and neck squamous cel...

    Authors: Sipeng Shen, Guanrong Wang, Qianwen Shi, Ruyang Zhang, Yang Zhao, Yongyue Wei, Feng Chen and David C. Christiani
    Citation: Clinical Epigenetics 2017 9:88
  23. Oral squamous cell carcinoma (OSCC) is usually diagnosed at an advanced stage and is commonly preceded by oral premalignant lesions. The mortality rates have remained unchanged (50% within 5 years after diagno...

    Authors: Luca Morandi, Davide Gissi, Achille Tarsitano, Sofia Asioli, Andrea Gabusi, Claudio Marchetti, Lucio Montebugnoli and Maria Pia Foschini
    Citation: Clinical Epigenetics 2017 9:85
  24. The epithelial-to-mesenchymal transition (EMT) enables epithelial cancer cells to acquire mesenchymal features and contributes to metastasis and resistance to treatment. This process involves epigenetic reprog...

    Authors: Emilie Evanno, Julie Godet, Nathalie Piccirilli, Joëlle Guilhot, Serge Milin, Jean Marc Gombert, Benoit Fouchaq and Joëlle Roche
    Citation: Clinical Epigenetics 2017 9:80
  25. Most DNA cancer methylation markers are based on the transcriptional regulation of the promoter-gene relationship. Recently, the importance of long-range interactions between distal CpGs and target genes has b...

    Authors: Seong-Min Park, Eun-Young Choi, Mingyun Bae, Jung Kyoon Choi and Youn-Jae Kim
    Citation: Clinical Epigenetics 2017 9:73
  26. The aim of this study was to explore the clinical utility of microRNAs (miRNAs) as improved markers of ovarian granulosa cell tumours (GCTs) for cancer diagnosis and prognosis prediction. Current histopatholog...

    Authors: Wei-Tzu Cheng, Roseanne Rosario, Anita Muthukaruppan, Michelle K Wilson, Kathryn Payne, Peter C. Fong, Andrew N. Shelling and Cherie Blenkiron
    Citation: Clinical Epigenetics 2017 9:72
  27. The DNA modification 5-hydroxymethylcytosine (5hmC) is now referred to as the sixth base of DNA with evidence of tissue-specific patterns and correlation with gene regulation and expression. This epigenetic ma...

    Authors: Noa Gilat, Tzlil Tabachnik, Amit Shwartz, Tamar Shahal, Dmitry Torchinsky, Yael Michaeli, Gil Nifker, Shahar Zirkin and Yuval Ebenstein
    Citation: Clinical Epigenetics 2017 9:70
  28. Aberrations in histone post-translational modifications (hPTMs) have been linked with various pathologies, including cancer, and could not only represent useful biomarkers but also suggest possible targetable ...

    Authors: Roberta Noberini, Rémi Longuespée, Cristina Richichi, Giancarlo Pruneri, Mark Kriegsmann, Giuliana Pelicci and Tiziana Bonaldi
    Citation: Clinical Epigenetics 2017 9:69
  29. This study examined Sal-like protein (SALL)3 methylation profiles of head and neck cancer (HNSCC) patients at diagnosis and follow-up and evaluated their prognostic significance and value as a biomarker. SALL3 ex...

    Authors: Kiyoshi Misawa, Daiki Mochizuki, Atsushi Imai, Yuki Misawa, Shiori Endo, Masato Mima, Hideya Kawasaki, Thomas E. Carey and Takeharu Kanazawa
    Citation: Clinical Epigenetics 2017 9:64
  30. Lung cancer is the leading cause of cancer-related deaths with 1.8 million new cases each year and poor 5-year prognosis. Promoter hypermethylation of tumour suppressors leads to their inactivation and thereby...

    Authors: Antje M. Richter, Steffen Kiehl, Nicole Köger, Janina Breuer, Thorsten Stiewe and Reinhard H. Dammann
    Citation: Clinical Epigenetics 2017 9:60
  31. Inclusion of new biomarkers to improve a personalized treatment approach for oropharyngeal squamous cell carcinoma (OPSCC) is urgently needed. Hypomethylation of the Long interspersed nucleotide element-1 (LIN...

    Authors: Carlo Furlan, Jerry Polesel, Luigi Barzan, Giovanni Franchin, Sandro Sulfaro, Salvatore Romeo, Francesca Colizzi, Aurora Rizzo, Vittorio Baggio, Vittorio Giacomarra, Angelo Paolo Dei Tos, Paolo Boscolo-Rizzo, Emanuela Vaccher, Riccardo Dolcetti, Luca Sigalotti and Elisabetta Fratta
    Citation: Clinical Epigenetics 2017 9:58
  32. In chronic lymphocytic leukemia (CLL), epigenomic and genomic studies have expanded the existing knowledge about the disease biology and led to the identification of potential biomarkers relevant for implement...

    Authors: Lata Rani, Nitin Mathur, Ritu Gupta, Ajay Gogia, Gurvinder Kaur, Jaspreet Kaur Dhanjal, Durai Sundar, Lalit Kumar and Atul Sharma
    Citation: Clinical Epigenetics 2017 9:57
  33. Two molecular pathways promote the development of colorectal cancer (CRC). One is termed “microsatellite stable” (MSS) whereas the other is characterized by “microsatellite instability” (MSI or MIN). In additi...

    Authors: Tamotsu Sugai, Masakazu Yoshida, Makoto Eizuka, Noriyuki Uesugii, Wataru Habano, Kouki Otsuka, Akira Sasaki, Eiichiro Yamamoto, Takayuki Matsumoto and Hiromu Suzuki
    Citation: Clinical Epigenetics 2017 9:55
  34. Colonoscopy is currently widely accepted as the gold standard for detection of colorectal cancer (CRC) providing detection of up to 95% of pre-cancerous lesions during the procedure. However, certain limitatio...

    Authors: Jean-François Rahier, Anne Druez, Laurence Faugeras, Jean-Paul Martinet, Myriam Géhénot, Eléonore Josseaux, Marielle Herzog, Jake Micallef, Fabienne George, Monique Delos, Thierry De Ronde, Abdenor Badaoui and Lionel D’Hondt
    Citation: Clinical Epigenetics 2017 9:53
  35. Targeting checkpoint inhibitors using monoclonal antibodies results in significantly better outcome of cancer patients compared to conventional chemotherapy. However, the current companion diagnostics to predi...

    Authors: Sebastian Marwitz, Swetlana Scheufele, Sven Perner, Martin Reck, Ole Ammerpohl and Torsten Goldmann
    Citation: Clinical Epigenetics 2017 9:51
  36. DIRAS1 is a new member of the Ras gene family. It was described as a potential tumor suppressor in human glioblastomas and esophageal cancer. The role of DIRAS1 in colorectal cancer re...

    Authors: Ruipan Zheng, Dan Gao, Tao He, Meiying Zhang, Xiaomei Zhang, Enqiang Linghu, Lixin Wei and Mingzhou Guo
    Citation: Clinical Epigenetics 2017 9:50
  37. The CpG island methylator phenotype (CIMP) in stage III colon cancer (CRC) has been associated with improved survival after treatment with adjuvant irinotecan-based chemotherapy. In this analysis, we determine...

    Authors: Stacey A. Cohen, Ming Yu, Kelsey Baker, Mary Redman, Chen Wu, Tai J. Heinzerling, Ralph M. Wirtz, Elpida Charalambous, George Pentheroudakis, Vassiliki Kotoula, Konstantine T. Kalogeras, George Fountzilas and William M. Grady
    Citation: Clinical Epigenetics 2017 9:46
  38. Papillary thyroid carcinoma (PTC) is a common endocrine neoplasm with a recent increase in incidence in many countries. Although PTC has been explored by gene expression and DNA methylation studies, the regula...

    Authors: Caroline Moraes Beltrami, Mariana Bisarro dos Reis, Mateus Camargo Barros-Filho, Fabio Albuquerque Marchi, Hellen Kuasne, Clóvis Antônio Lopes Pinto, Srikant Ambatipudi, Zdenko Herceg, Luiz Paulo Kowalski and Silvia Regina Rogatto
    Citation: Clinical Epigenetics 2017 9:45
  39. Long non-coding RNAs (lncRNAs) have emerged as key players in a remarkably variety of biological processes and pathologic conditions, including cancer. Next-generation sequencing technologies and bioinformatic...

    Authors: Pelayo G. de Lena, Abel Paz-Gallardo, Jesús M. Paramio and Ramón García-Escudero
    Citation: Clinical Epigenetics 2017 9:36
  40. Colorectal cancers (CRCs) undergo distinct genetic and epigenetic alterations. Expression of mutL homolog 1 (MLH1), a mismatch repair gene that corrects DNA replication errors, is lost in up to 15% of sporadic tu...

    Authors: Andrea J. Savio, Miralem Mrkonjic, Mathieu Lemire, Steven Gallinger, Julia A. Knight and Bharat Bapat
    Citation: Clinical Epigenetics 2017 9:26
  41. Conventional tubular adenomas are frequently detected in patients undergoing average risk screening colonoscopy and are over-represented in patients who will develop colorectal cancer (CRC). Whether features o...

    Authors: Alice Chu Jiang, Lela Buckingham, William Barbanera, Amoah Yeboah Korang, Faraz Bishesari and Joshua Melson
    Citation: Clinical Epigenetics 2017 9:25

    The Erratum to this article has been published in Clinical Epigenetics 2017 9:76

  42. Colorectal cancer (CRC) is the third most common cancer worldwide. If detected at an early stage, prognosis is good. Despite increasing evidence for the benefits of implemented screening programs, such as scre...

    Authors: Jonathan Alexander Heiss and Hermann Brenner
    Citation: Clinical Epigenetics 2017 9:24
  43. MiRNA expression markers are well characterized in colorectal cancer (CRC), but less is known about miRNA expression profiles in colorectal adenomas. Genome-wide miRNA and mRNA expression analyses were conduct...

    Authors: Zsófia Brigitta Nagy, Barnabás Wichmann, Alexandra Kalmár, Orsolya Galamb, Barbara Kinga Barták, Sándor Spisák, Zsolt Tulassay and Béla Molnár
    Citation: Clinical Epigenetics 2017 9:22
  44. Alteration of DNA methylation (5-methylcytosine, 5mC) patterns represents one of the causes of tumorigenesis and cancer progression. Tet proteins can oxidise 5mC to 5-hydroxymethylcytosine (5hmC), 5-formylcyto...

    Authors: Ashley Ramsawhook, Lara Lewis, Beth Coyle and Alexey Ruzov
    Citation: Clinical Epigenetics 2017 9:18
  45. Oral squamous cell carcinoma (OSCC) is one of the common malignancies in Southeast Asia. Epigenetic changes, mainly the altered DNA methylation, have been implicated in many cancers. Considering the varied env...

    Authors: Baidehi Basu, Joyeeta Chakraborty, Aditi Chandra, Atul Katarkar, Jadav Ritesh Kumar Baldevbhai, Debjit Dhar Chowdhury, Jay Gopal Ray, Keya Chaudhuri and Raghunath Chatterjee
    Citation: Clinical Epigenetics 2017 9:13
  46. Molecular biomarkers assisting risk-group assignment and subsequent treatment stratification are urgently needed for patients with squamous cell cancer of the head and neck region (HNSCC). Aberrant methylation...

    Authors: Verena Sailer, Emily Eva Holmes, Heidrun Gevensleben, Diane Goltz, Freya Dröge, Alina Franzen, Jörn Dietrich, Glen Kristiansen, Friedrich Bootz, Andreas Schröck and Dimo Dietrich
    Citation: Clinical Epigenetics 2017 9:12
  47. Differentially methylated regions (DMRs) within DNA isolated from whole blood can be used to estimate the proportions of circulating leukocyte subtypes. We use the term “immunomethylomics” to describe the appl...

    Authors: John K. Wiencke, Devin C. Koestler, Lucas A. Salas, Joseph L. Wiemels, Ritu P. Roy, Helen M. Hansen, Terri Rice, Lucie S. McCoy, Paige M. Bracci, Annette M. Molinaro, Karl T. Kelsey, Margaret R. Wrensch and Brock C. Christensen
    Citation: Clinical Epigenetics 2017 9:10